Pharmaceuticals 2010, 3(7), 2146-2162; doi:10.3390/ph3072146
Review

Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks

Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente and University of Twente, Ariensplein 1, 7500 KA Enschede, The Netherlands
* Author to whom correspondence should be addressed.
Received: 17 June 2010; in revised form: 30 June 2010 / Accepted: 1 July 2010 / Published: 7 July 2010
(This article belongs to the Special Issue Non-Steroidal Anti-Inflammatory Drugs)
PDF Full-text Download PDF Full-Text [163 KB, uploaded 7 July 2010 08:54 CEST]
Abstract: While aspirin may offer protection, other non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) can cause serious cardiovascular side effects and complications. This has led to a general "black box" warning for cardiovascular adverse events for NSAIDs. This review explores the different mechanisms underlying the protective effects of aspirin, the NSAID associated renovascular effects causing hypertension, edema and heart failure, the cardiovascular effects causing myocardial infarction and stroke, and the possible deleterious interaction between NSAIDs and aspirin.
Keywords: NSAIDs; aspirin; cardiovascular events

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Meek, I.L.; Van de Laar, M.A.; E. Vonkeman, H. Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks. Pharmaceuticals 2010, 3, 2146-2162.

AMA Style

Meek IL, Van de Laar MA, E. Vonkeman H. Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks. Pharmaceuticals. 2010; 3(7):2146-2162.

Chicago/Turabian Style

Meek, Inger L.; Van de Laar, Mart A.F.J.; E. Vonkeman, Harald. 2010. "Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks." Pharmaceuticals 3, no. 7: 2146-2162.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert